6533b852fe1ef96bd12ab621

RESEARCH PRODUCT

Peptide Receptor Radionuclide Therapy for Neuroendocrine Neoplasms in Germany: a Multi-Institutional Registry Study with Prospective Follow Up on 450 Patients

Samer EzziddinAlexander HaugMatthias MiedererDieter HörschBernd J. KrauseS. DunkelmannGabriele PöpperlRichard A. BaumHans-jürgen BiersackK. F. Gratz

subject

medicine.medical_specialtyPediatricsgenetic structuresPeptide receptorbusiness.industryRegistry studyHematologyNeuroendocrine tumorsmedicine.diseaseOncologyRadionuclide therapyotorhinolaryngologic diseasesmedicineIn patientRadiologyReceptorbusinesspsychological phenomena and processes

description

68 Ga-DOTATOC PET in patients with neuroendocrine tumors (NET). We specifically looked for incremental lesions, defined as lesions only observed on one modality even after extensive retrospective evaluation of the other modality. Methods: Twenty patients with a metastasized NET underwent 111 In-pentetreotide

https://doi.org/10.1093/annonc/mdt201.5